Jan Marin1, Greta Lipa2, Eric Dunet2. 1. GH Nord Essonne, Longjumeau, France; Obstetrics and gynecology service, France. Electronic address: j.marin@gh-nord-essonne.fr. 2. GH Nord Essonne, Longjumeau, France; Plastic surgery service, France.
Abstract
OBJECTIVES: The aim of this research was to assess the efficacy of the new generation micro-fractional CO2 laser low dose energy (Aphrodite, BH LASER, France) in the treatment of genitourinary syndrome. MATERIALS AND METHODS: This prospective interventional clinical study, included a total of 25 menopausal symptomatic patients and 25 non-menopausal symptomatic patients having symptoms of vulvovaginal atrophy. There were only two laser sessions spaced at 6 weeks. It was evaluated the Female Sexual Function Index (FSFI) and the QoL at baseline, 3 and 6 months. RESULTS: The study showed a significant improvement in both groups when assessing FSFI scores at 3- and 6-months follow-up compared to baseline (p<0.05) and secondary it was observed a significant initial improvement of QoL score at 3 and 6 months (p<0.05), compared to baseline. There were no important adverse events registered during the study period. CONCLUSIONS: The new micro-fractionated laser device with low dose energy - 18W, demonstrated significant improvement of genitourinary syndrome in both non-menopausal and post-menopausal women with no important adverse event.
OBJECTIVES: The aim of this research was to assess the efficacy of the new generation micro-fractional CO2 laser low dose energy (Aphrodite, BH LASER, France) in the treatment of genitourinary syndrome. MATERIALS AND METHODS: This prospective interventional clinical study, included a total of 25 menopausal symptomatic patients and 25 non-menopausal symptomatic patients having symptoms of vulvovaginal atrophy. There were only two laser sessions spaced at 6 weeks. It was evaluated the Female Sexual Function Index (FSFI) and the QoL at baseline, 3 and 6 months. RESULTS: The study showed a significant improvement in both groups when assessing FSFI scores at 3- and 6-months follow-up compared to baseline (p<0.05) and secondary it was observed a significant initial improvement of QoL score at 3 and 6 months (p<0.05), compared to baseline. There were no important adverse events registered during the study period. CONCLUSIONS: The new micro-fractionated laser device with low dose energy - 18W, demonstrated significant improvement of genitourinary syndrome in both non-menopausal and post-menopausal women with no important adverse event.